Effect of metformin on sputum smear conversion in pulmonary tuberculosis with type 2 diabetes mellitus

Phase 3

• Conditions: Pulmonary tuberculosis Type 2 diabetes mellitus Metformin; Tuberculosis, Pulmonary; Diabetes Mellitus, Type 2; Metformin

• Registration Number: TCTR20190128004
• Lead Sponsor: Khon Kaen Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2019-01-28
• Study Completion: 2019-05-31
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Patients who are newly diagnosed pulmonary tuberculosis and enroll in the nested RCT “Efficacy of N-acetylcysteine in sputum smear conversion in pulmonary tuberculosis; multicenter open label pragmatic randomized controlled trial” - TCTR identification number is TCTR20190128002

Patients who diagnosed type 2 diabetes mellitus

Exclusion Criteria

There is no exclusion criteria in this study

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sputum smear (AFB) conversion At the end of 2, 4, 8 and 12 weeks after anti-TB treatment event rate

Secondary Outcome Measures

Name	Time	Method
Doses of metformin that are associated with sputum smear conversion At the end of 2, 4, 8 and 12 weeks after anti-TB treatment event rate of sputum smear conversion at each dose,Adverse events Along period of study event rate,Hospital admission from any causes Along period of study event rate,Rate of multi-drug resistant tuberculosis Along period of study event rate